Clinical trial
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and…
NCT00122460 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00122460 |
|---|---|
| Title | Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) |
| Official title | Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU), Platinum (Cisplatin or Carboplatin) + 5-FU |
| Enrollment | 442 |
| Start date | Dec 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Jan 1, 2011 |
| First posted | Jul 22, 2005 |
| Last update posted | Jul 23, 2014 |
| Countries | Austria, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Russia, Slovakia and 5 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: